Ryosuke Watari
Toyonaka, 5610825, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate.
Journal: Pharmaceutics
Published: October 21, 2025
Evaluation of OATP1B inhibitory potential using an endogenous biomarker coproporphyrin-I in new drug applications: Case reports submitted by 2024.
Journal: Drug metabolism and pharmacokinetics
Published: September 24, 2025
Novel Approach to Pre-Exposure Prophylaxis (PrEP) of COVID-19: Development of S-892216 Long-Acting Injectable Suspension.
Journal: Chemical & pharmaceutical bulletin
Published: August 12, 2025
Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19.
Journal: Journal of medicinal chemistry
Published: July 05, 2025
Investigation of an OATP1B inhibitory effect by a cyclic peptide using the endogenous biomarker coproporphyrin-I in monkeys.
Journal: Drug metabolism and pharmacokinetics
Published: February 25, 2025
Minimal Involvement of P-gp and BCRP in Oral Absorption of Ensitrelvir, An Oral SARS-CoV-2 3C-like Protease Inhibitor, in a Non-Clinical Investigation.
Journal: Journal of pharmaceutical sciences
Published: April 17, 2024
Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Journal: Antiviral research
Published: November 29, 2023
Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery.
Journal: Drug metabolism and pharmacokinetics
Published: October 18, 2023
Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
Journal: Journal of pharmaceutical sciences
Published: August 20, 2023
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Journal: The Journal of antimicrobial chemotherapy
Published: October 17, 2022
Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: May 31, 2022
Discovery of 2-Sulfinyl-Diazabicyclooctane Derivatives, Potential Oral β-Lactamase Inhibitors for Infections Caused by Serine β-Lactamase-Producing Enterobacterales.
Journal: Journal of medicinal chemistry
Published: June 18, 2021
Last Updated: 09/26/2026